This ADC product is comprised of an anti-TPBG monoclonal antibody (V422C) conjugated via a Mc linker to MMAD. The MMAD is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell,
* VAT and and shipping costs not included. Errors and price changes excepted